Compare Amgen, Inc. (AMGN) vs Build A Bear Workshop Inc (BBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Build A Bear Workshop Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Build A Bear Workshop Inc trades at $34.65 (market cap $431.54M). The key difference: Amgen, Inc. is far larger — about 454.5× Build A Bear Workshop Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BBW | |
|---|---|---|
Market Cap | $196.12B | $431.54M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $75.85 |
52-Week Low | $271.18 | $29.84 |
Enterprise Value | $241.41B | $530.98M |
Dividend Yield | 2.77% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Build-A-Bear Workshop (BBW) trades at $34.42, up 10.5% today, showing strong momentum despite a bearish technical outlook. The company demonstrates solid fundamentals with a P/E of 8.06 and robust profitability metrics including 35.87% ROE. Recent Q1 2026 earnings beat expectations with $1.03 EPS versus $0.76 estimate, though revenue guidance was revised downward. The company completed a planned CEO transition in June 2026 and maintains a debt-free balance sheet with consistent dividend payments.
BBW presents a compelling value opportunity with attractive valuation multiples and strong analyst support (72.7% buy ratings, $62.50 consensus target). However, near-term headwinds include consumer spending pressures and international expansion execution risks. The stock's 40% YTD decline creates potential for recovery if the company can successfully implement its four-pillar growth strategy in the second half of 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →
